Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Disease mechanisms

Topic: Brain proteins, microglia and lab models

Plain-language summary

The basal nucleus showed significant neuronal loss in PPA versus controls (p <0.05). It also had the most total tau inclusions, significantly more than the accessory basal (p <0.01-0.05) and central (both p <0.05) nuclei. The lateral nucleus of PPA/3R cases demonstrated significant neuronal loss versus other nuclei (p <0.01-0.05) and pathologic groups (both p <0.01). PPA/3R showed higher total tau inclusions than PPA/4R across all nuclei (p <0.01-0.05) due to prevalent intraneuronal inclusions. In contrast, PPA/4R had more glial pathology, particularly in the central nucleus (p <0.05). Left %AT-8 was greater than right in bilaterally sectioned PPA/4R cases (p <0.001). Findings highlight distinct vulnerabilities of amygdala nuclei in PPA due to FTLD-tauopathies. Irrespective of tauopathy, the basal nucleus showed the greatest neuronal loss and tau pathology in PPA. PPA/3R showed more global tau accumulation and lateral nucleus neuronal loss, whereas PPA/4R demonstrated greater central nucleus glial tau accumulation. Results also demonstrate leftward asymmetry of pathogenesis in PPA, even in limbic regions. Future investigation of neuroinflammation and synaptic markers may yield additional insights into these vulnerabilities.

What this study adds

Evidence grade: Low

This brain tissue study found that different amygdala nuclei are unequally damaged in primary progressive aphasia due to FTLD-tauopathies, with the basal nucleus showing the most neuronal loss and tau pathology. It describes patterns of damage only and does not test any treatment, so it offers no direct path to treating or preventing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Keszycki, R. M., Ayala, I., Zouridakis, A., Kawles, A., Macomber, A., Nelson, C. M., et al. (2025). Amygdala nuclei are not uniformly vulnerable to FTLD‐tauopathies in PPA. Alzheimer s & Dementia. https://doi.org/10.1002/alz70855_107447

Vancouver

Keszycki RM, Ayala I, Zouridakis A, Kawles A, Macomber A, Nelson CM, et al. Amygdala nuclei are not uniformly vulnerable to FTLD‐tauopathies in PPA. Alzheimer s & Dementia. 2025. doi:10.1002/alz70855_107447. PMID: 41446915.

BibTeX

@article{keszycki2025-41446915,
  author  = {Keszycki, Rachel M. and Ayala, Ivan and Zouridakis, Antonia and Kawles, Allegra and Macomber, Alyssa and Nelson, Caroline M and Minogue, Grace and Weıntraub, Sandra and others},
  title   = {{Amygdala nuclei are not uniformly vulnerable to FTLD‐tauopathies in PPA}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70855_107447},
  pmid    = {41446915},
  url     = {https://doi.org/10.1002/alz70855_107447}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This brain tissue study found that different amygdala nuclei are unequally damaged in primary progressive aphasia due to FTLD-tauopathies, with the basal nucleus showing the most neuronal loss and tau pathology. It describes patterns of damage only and does not test any treatment, so it offers no direct path to treating or preventing Alzheimer's disease.

Study details

How this study scored 33/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 33 of 100.33 of 100 points earned67 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Tamar D. Gefen: h-index 25 (OpenAlex, whole career)
Institution's track record 2 / 3 Northwestern University: institution h-index 1,592 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41446915)
Free to read 2 / 2 Free to read
Total 33 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Disease mechanisms from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Disease mechanisms

See all studies in Disease mechanisms →